临床PI
孟志强 教授
教授、博士生导师
E-mail: mengzhq@yeah.net
 

  1999年毕业于上海医科大学获得博士学位。2004年在美国M.D. Anderson肿瘤中心学习。现任复旦大学附属肿瘤医院微创治疗中心/中西医结合科主任、美国M.D. Anderson肿瘤中心兼职教授。中国临床肿瘤学会肿瘤消融治疗专家委员会主任委员、上海市抗癌协会肿瘤微创治疗委员会主任委员、中国医师协会微无创医学专业委员会副主任委员、中国抗癌协会肿瘤微创治疗委员会常委、国际肝胆胰协会中国分会介入治疗专业委员会副主任委员、上海市中西医结合学会胰腺病专业委员会副主任委员、上海中西医结合学会肝病专业委员会副主任委员、上海市抗癌协会理事、亚洲肿瘤消融学会理事等职。
  2011年获得上海市科技进步二等奖和教育部科技进步二等奖;2012年获得中西医结合学会一等奖;2012年获得明治生命科学奖;2016年获得上海市科技进步一等奖。入选上海市“百人计划”。作为项目负责人主持美国NIH/NCI-R01、U19项目、国家自然科学基金(三项)、上海市科委重点项目等10余项,立项经费1800万。在Gastroenterology、Oncogene、Mol Oncol、Brit J Cancer、Eur J Cancer、Cancer等发表论文95篇,他引超过1500次,H-index:23。批准专利2项。主持临床研究16项。


研究领域:

  肝、胆、胰腺肿瘤的耐药机制及微创治疗对策研究
  1. Na+K+ATP酶在肝癌的功能研究及药物筛选;
  2. 炎性微环境与肝胰腺肿瘤肿瘤的耐药机制;
  3. 肿瘤微创治疗的临床研究。


代表性论著:

  1. Zhang C, Wang H, Chen Z, Zhuang L, Xu L, Ning Z, Zhu Z, Wang P, Meng Z*. Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Carcinogenesis. 2018 Apr 5; 39(4):562-570.
  2. Wang H, Zhang C, Chi H, Meng Z*. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. Int J Oncol, 2018 Apr 2. [Epub ahead of print]
  3. Wang, Q., Qu, C., Xie, F., Chen, L., Liu, L., Liang, X., Meng, Z*. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. American Journal of Cancer Research, 2017; 7(1), 125-133.
  4. Milbury, K, Kavanagh, A, Meng, Z*, Chen, Z, Chandwani, KD, Garcia, K, Perkins, GH, McQuade, J, Raghuram, NV, Nagarathna, R, Liao, Z, Nagendra, HR, Chen, J, Guo, X, Liu, L, Arun, B & Cohen, L. Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Supportive Care in Cancer, 2017 Jul; 25(7):2103-2109.
  5. Xie, J, Chen, LH, Ning, ZY, Zhang, CY, Chen, H, Chen, Z, Meng, Z*, Zhu, XY. Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: A single-blind, randomized, controlled trial. Chinese Journal of Cancer, 2017 Jan 10; 36(1):6.
  6. Zhang, C., Wang, H., Ning, Z., Xu, L., Zhuang, L., Wang, P., & Meng, Z. Q*. Hyperfibrinogen is associated with the systemic inflammatory response and predicts poor prognosis in intrahepatic cholangiocarcinoma. International Journal of Clinical and Experimental Medicine. 2017; 10(3): 5670-5677.
  7. Liu, F, Meng, Z*, Shao, G, Wang, J, Wang, Z, Yang, J, Yip, CSM & He, D. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Molecular Biology Reports, 2017; 44(1):149-158.
  8. Zhang C, Wang H, Ning Z, Xu L, Zhuang L, Wang P, Meng Z*. Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma. Onco Targets Ther, 2017 Mar 6; 10: 1441-1449.
  9. Ning, ZY, Cheng, CS, Xie, J, Chen, QW, Xu, LT, Zhuang, L, Zhang, CY, Song, LB, Shi, WD, Zhu, XY, Wang, P, Wang, K, Meng, ZQ*. A retrospective analysis of survival factors of High Intensity Focused Ultrasound (HIFU) treatment for unresectable pancreatic cancer. Discovery Medicine. 2016 Jun; 21(118):435-45.
  10. Wang, H, Ning, Z, Li, Y, Zhu, X, Meng Z*. Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via hedgehog signaling. Molecular Medicine Reports, 2016; 14(3), 1907-1914.
  11. Wang H, Zhang C, Ning Z, Xu L, Zhu X, Meng Z*. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. Int J Oncol, 2016 Mar; 48(3):1229-41.
  12. Zhuang L, Xu L, Wang P, Jiang Y, Yong P, Zhang C, Zhang H, Meng Z*, Yang P. Na+/K+-ATPase 1 subunit, a novel therapeutic target for hepatocellular carcinoma. Oncotarget, 2015; 6(29):28183-93.
  13. Shen Y, Pan Y, Xu L, Chen L, Liu L, Chen H, Chen Z, Meng Z*. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol, 2015; 36(6):4525-34.
  14. Wang SY, Feng LY, Meng ZQ*. Bicluster and pathway enrichment analysis related to tumor progression of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2015; 19(7):1191-7.
  15. Zhuang LP, Meng ZQ*. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int, 2015; 2015:731781.
  16. Zhuang L, Xu L, Wang P, Meng Z*. Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma. PLoS One, 2015 Feb 2; 10(2):e0117274.
  17. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng ZQ*. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene, 2014; 33(4):514-24.
  18. Shi W, Yin J, Chen Z, Chen H, Liu L, Meng Z*. Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27. Tumour Biol, 2014 Nov; 35(11):11147-51.
  19. Wang H, Xu L, Zhu X, Wang P, Chi H, Meng ZQ*. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. Oncol Rep, 2014; 32(4):1465-72.
  20. Chen QW, Cheng CS, Chen H, Ning ZY, Tang SF, Zhang X, Zhu XY, Vargulick S, Shen YH, Hua YQ, Xie J, Shi WD, Gao HF, Xu LT, Feng LY, Lin JH, Chen Z, Liu LM, Ping B, Meng ZQ*. Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤200 ng/ml--a study based on 4,312 patients. PLoS One, 2014; 9(8):e101536.
  21. Chen QW, Chen H, Cheng JS, Meng ZQ*. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis. Tumour Biol, 2014; 35(5):4147-51.
  22. Chen QW, Zhu XY1, Li YY2, Meng ZQ*. Epigenetic regulation and cancer (review). Oncol Rep, 2014; 31(2):523-32.
  23. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, Chen Z, Meng Z*. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology, 2013; 145(5):1133-1143.e12.
  24. Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z*. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol, 2013; 7(3):334-45.
  25. Wang P, Zhang L, Chen Z, Meng Z*. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Autophagy, 2013; 9(12):2171-2.
  26. Chen Q, Zhu X, Chen Q, Wang K, Meng ZQ*. Unresectable giant pancreatic neuroendocrine tumor effectively treated by high-intensity focused ultrasound: a case report and review of the literature. Pancreatology, 2013; 13(6):634-8.
  27. Xie J, Chen Z, Liu L, Li P, Zhu X, Gao H, Meng Z*. shRNA-mediated Slc38a1 silencing inhibits migration, but not invasiveness of human pancreatic cancer cells. Chin J Cancer Res, 2013; 25(5):514-9.
  28. Zhuang L, Zeng X, Yang Z, Meng Z*. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One, 2013; 8(9):e61361.
  29. Wang S, Zhuang L, Meng Z*. Hepatocellular Carcinoma More Than 3 cm in Diameter: A Systematic Review of Transcatheter Arterial Chemoembolization Plus Percutaneous Ethanol Injection versus Transcatheter Arterial Chemoembolization Alone. ISRN Gastroenterol, 2013; 2013:526024.
  30. Wang K, Zhu H, Meng Z*, Chen Z, Lin J, Shen Y, Gao H. Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. Onkologie, 2013; 36(3):88-92.
  31. Zhuang L, Yang Z, Zeng X, Zhua X, Chen Z, Liu L, Meng Z*. The preventive and therapeutic effect of acupuncture for radiation-induced xerostomia in patients with head and neck cancer: a systematic review. Integr Cancer Ther, 2013; 12(3):197-205.
  32. Gao HF, Wang K, Meng ZQ*, Chen Z, Lin JH, Zhou ZH, Wang P, Shi WD, Sheng YH. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology, 2013; 60(128):1906-10.
  33. Meng Z*, Garrett CR,Shen Y,Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, Cohen L . Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer, 2012; 107(3):411-6.
  34. Meng Z*, Kay Garcia M, Hu C, Chiang J, Chambers M, Rosenthal DI, Peng H, Wu C, Zhao Q, Zhao G, Liu L, Spelman A, Lynn Palmer J, Wei Q, Cohen L. Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Eur J Cancer, 2012; 48(11):1692-9.
  35. Meng Z*, Garcia MK, Hu C, Chiang J, Chambers M, Rosenthal DI, Peng H, Zhang Y, Zhao Q, Zhao G, Liu L, Spelman A, Palmer JL, Wei Q, Cohen L. Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Cancer, 2012; 118(13):3337-44.
  36. Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen L, Yang PY, Gu K, Meng ZQ*. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Mol Biol Rep, 2012; 39(2):1683-9.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有